NYSE$IBIO
iBio Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Announced financial results for the fiscal quarter ended December 31, 2020.
iBio reported an increase in revenue to $0.7 million, up from $0.3 million in the same quarter of the previous year. The company's operating expenses increased to $8.3 million, and the net loss attributable to iBio stockholders was $8.2 million, or $0.04 per share. As of December 31, 2020, iBio had cash and cash equivalents plus investments in debt securities of approximately $107.6 million.
- Revenue increased by $0.4 million compared to the same quarter last year.
- Operating expenses increased primarily due to higher R&D and G&A expenses.
- Net loss decreased significantly compared to the same period in 2019, primarily due to deemed dividends in the previous year.
- Cash and cash equivalents plus investments in debt securities totaled approximately $107.6 million as of December 31, 2020.
Headline financials
Revenue & EPS history
iBio · Revenue · Quarterly
$705K
Forward guidance
The company is focused on advancing its pipeline, diversifying its customer base, and growing revenues. They believe they are well positioned to accelerate the development of biotherapeutic and vaccine candidates, in-license promising biopharmaceutical assets, and leverage the FastPharming System.
Tailwinds
- Advancing vaccine programs.
- Securing additional IP protection for antifibrotic therapies.
- Expanding client base for CDMO Services.
- Rapidly advancing work on new RBP products.
- Building a world-class organization with key appointments.
Headwinds
- The company does not provide specific negative guidance in the earnings report. Therefore, I'm unable to provide 5 negative bullet points.
- The company does not provide specific negative guidance in the earnings report. Therefore, I'm unable to provide 5 negative bullet points.
- The company does not provide specific negative guidance in the earnings report. Therefore, I'm unable to provide 5 negative bullet points.
- The company does not provide specific negative guidance in the earnings report. Therefore, I'm unable to provide 5 negative bullet points.
- The company does not provide specific negative guidance in the earnings report. Therefore, I'm unable to provide 5 negative bullet points.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
-1.4%
Avg return
Earnings day
-2.9%
Avg return
5 days after
+14.3%
Avg return
30 days after
43%
17 / 40 earnings
Positive
+24.4%
Q3 2020
Best reaction
-34.4%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | +12.9% | +9.9% | +22.8% | |
| Q1 2026 | -8.0% | -3.2% | +55.2% | |
| Q4 2025 | +3.7% | +8.6% | +6.2% | |
| Q3 2025 | +1.3% | +1.3% | +30.4% | |
| Q2 2025 | -14.8% | -7.8% | +49.2% | |
| Q1 2025 | -9.4% | -10.9% | -2.0% | |
| Q4 2024 | -2.6% | -4.2% | +51.1% | |
| Q3 2026 | -3.7% | +23.9% | +36.2% | |
| Q3 2024 | +1.6% | +7.0% | +37.8% | |
| Q2 2024 | +5.2% | +5.2% | +2.6% | |
| Q1 2024 | -3.4% | -10.3% | -78.1% | |
| Q4 2023 | -3.3% | -9.1% | -6.1% | |
| Q3 2023 | -7.9% | -5.9% | -31.7% | |
| Q2 2023 | -10.5% | +55.8% | +113.7% | |
| Q1 2023 | +0.0% | -8.6% | -68.6% | |
| Q4 2022 | -34.4% | -46.9% | -74.6% | |
| Q3 2022 | +0.0% | +0.0% | +12.0% | |
| Q2 2022 | +2.7% | -8.1% | -5.4% | |
| Q1 2022 | -9.2% | -11.8% | -17.1% | |
| Q4 2021 | -4.3% | -11.1% | -35.0% | |
| Q3 2021 | -6.8% | -0.7% | +5.4% | |
| Q2 2021 | -15.3% | -17.8% | -29.8% | |
| Q1 2021 | +15.2% | -9.6% | -38.2% | |
| Q3 2020 | +24.4% | +16.0% | +31.9% | |
| Q2 2020 | -10.5% | -21.1% | +321.1% | |
| Q1 2020 | +13.3% | -26.7% | +46.7% | |
| Q3 2019 | +7.3% | -2.4% | -4.9% | |
| Q2 2019 | -2.2% | -4.4% | -6.7% | |
| Q1 2019 | +4.0% | +9.3% | -10.7% | |
| Q1 2015 | +3.4% | — | — | |
| Q1 2014 | +0.0% | — | — | |
| Q1 2013 | -1.9% | — | — | |
| Q3 2012 | -9.8% | — | — | |
| Q1 2010 | +1.8% | — | — | |
| Q1 2012 | +1.8% | — | — | |
| Q4 2011 | -3.0% | — | — | |
| Q3 2011 | +4.8% | — | — | |
| Q2 2010 | +3.4% | — | — | |
| Q4 2010 | +1.4% | — | — | |
| Q3 2010 | -1.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro